Mucosolvan Mini (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan Mini, is a mucolytic presented as an oral formulation for oral use. It helps to loosen and clear thick respiratory secretions, facilitating easier cough and improving breathing in patients, particularly adults and children with acute or chronic respiratory conditions.

GNH USA supplies Mucosolvan Mini as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance and reliable delivery across global markets.

Ambroxol Hydrochloride acts on the respiratory mucus system to improve clearance in various conditions.

Acute bronchitis: reduces mucus viscosity, aiding expectoration and relieving cough. Chronic obstructive pulmonary disease (COPD) exacerbations: facilitates sputum clearance, supporting airway patency. Pneumonia: assists in thinning secretions, helping patients clear infected mucus more effectively.

Ambroxol Hydrochloride is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild gastrointestinal upset reported in some patients. - Taste disturbance: a temporary bitter or metallic taste. - Diarrhoea: loose stools, usually transient. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Allergic reactions: including urticaria, angioedema, or anaphylaxis. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes or hepatitis in rare cases.

When using Ambroxol Hydrochloride, consider the following precautions.

Assess liver function: monitor patients with known hepatic impairment. Avoid in known hypersensitivity: discontinue if allergic reactions occur. Use with caution in asthma: monitor for bronchospasm. Do not combine with other mucolytics without medical advice. Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Ambroxol Hydrochloride may interact with several medicines; awareness helps minimise risk.

Major Interactions (Avoid): - Antitussives containing codeine: may reduce mucolytic efficacy. - Concurrent use of other mucolytics: risk of excessive mucus thinning. - Monoamine oxidase inhibitors (MAOIs): potential for rare adverse reactions.

Moderate Interactions (Monitor Closely): - Antibiotics: may increase gastrointestinal side effects. - Antihistamines: may mask improvement in cough. - Bronchodilators: generally safe but monitor therapeutic response.